Jade Biosciences (Nasdaq: JBIO) released preclinical data for JADE301, an investigational anti-interferon beta (IFN-β) monoclonal antibody in development for dermatomyositis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE